Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

63.92
+1.532.45%
Volume:984.29K
Turnover:62.23M
Market Cap:7.87B
PE:-9.77
High:63.92
Open:61.95
Low:61.89
Close:62.39
52wk High:70.98
52wk Low:29.31
Shares:123.16M
Float Shares:119.09M
Volume Ratio:0.57
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5400
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-27.08%
PB:-11.93
PE(LYR):-9.77

Loading ...

Cytokinetics management to meet with B. Riley

TIPRANKS
·
Feb 28

Cytokinetics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Feb 27

Cytokinetics price target raised to $67 from $66 at BofA

TIPRANKS
·
Feb 26

Evercore ISI Keeps Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Feb 25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Evolent Health (EVH), Medtronic (MDT) and Cytokinetics (CYTK)

TIPRANKS
·
Feb 25

Cytokinetics price target raised to $96 from $88 at Citizens

TIPRANKS
·
Feb 25

Cytokinetics Is Maintained at Buy by Needham

Dow Jones
·
Feb 25

Cytokinetics Inc : Needham Raises Target Price to $85 From $84

THOMSON REUTERS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

Earnings Flash (CYTK) Cytokinetics Posts Q4 Loss $-1.50, vs. FactSet Est of Loss of $-1.56

MT Newswires Live
·
Feb 25

Cytokinetics Q4 EPS $(1.50) Misses $(1.45) Estimate, Sales $17.755M Beat $6.911M Estimate

Benzinga
·
Feb 25

BRIEF-Cytokinetics Q4 Basic EPS USD -1.5

Reuters
·
Feb 25

Cytokinetics Q4 net loss widens to USD 183.0 million (+22.0%)

Reuters
·
Feb 25

Cytokinetics Q4 Net Income USD -183.031 Million

THOMSON REUTERS
·
Feb 25

Cytokinetics Inc: Provides 2026 Financial Guidance With $1.2 Bln in Cash, Cash Equivalents and Investments as of December 31, 2025

THOMSON REUTERS
·
Feb 25

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
Feb 25

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 24

Cytokinetics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Feb 20

RBC Raises Price Target on Cytokinetics to $101 From $95, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Feb 20

RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
Feb 20